Zhongguo fei ai za zhi = Chinese journal of lung cancer
-
Lung cancer is the most common cause of cancer death worldwide. Early diagnosis and early treatment are of great importance. ⋯ In recent years, researchers all over the world have done lots of work on finding and identifying biomarkers for the early diagnosis of lung cancer. In this paper, recent developments in this field are reviewed.
-
Zhongguo Fei Ai Za Zhi · Feb 2011
[Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].
Approximately 35%-40% of patients with newly diagnosed non-small cell Lung cancer have locally advanced disease. The average survival time of these patients only have 6-8 months with chemotherapy. The aim of this study is to explore and summarize the probability of detection of micrometastasis in peripheral blood for molecular staging, and for selection of indication of surgical treatment, and beneficiary of neoadjuvant chemotherapy and postoperative adjuvant therapy in locally advanced lung cancer; to summarize the long-time survival result of personalized surgical treatment of 516 patients with locally advanced non-small cell lung cancer based on molecular staging methods. ⋯ (1) Micrometastasis was existed in peripheral blood of patients with lung cancer, which can not be detected with conventional methods. (2) Detecting of CK19 mRNA expression in peripheral blood in lung cancer patients can be used for diagnosis of micrometastasis of lung cancer and "molecular staging" and "molecular P-TNM staging" for lung cancer patients. It will be helpful for selection of surgical treatment indication, the beneficiary of neoadjuvant chemotherapy and postoperative adjuvant therapy in the patients with locally advanced non-small cell lung cancer. (3) Personalized surgical treatment can significantly improve prognosis and increase curative rate and long-term survival rate of locally advanced nonsmall cell lung cancer based on personalized molecular staging.
-
Zhongguo Fei Ai Za Zhi · Nov 2010
Meta Analysis[A meta analysis of aidi injection plus taxotere and cisplatin in the treatment of non-small cell lung cancer].
Compared with chemotherapy, whether aidi injection can improve the patient's quality of life is not definite. The aim of this study is to evaluate the efficacy and safety of axotere plus eisplatin chemotherapy combining aidi injection for patients with non-small cell lung cancer (NSCLC). ⋯ Compared with TP chemotherapy alone, the combination can significantly improve the efficiency, QOL and myelosuppression, and reduce adverse events.
-
Zhongguo Fei Ai Za Zhi · Sep 2010
Meta Analysis[A meta-analysis of the timing of chest radiotherapy in patients with limited-stage small cell lung cancer].
Although evidence for a significant survival benefit of chest radiotherapy has been proven, no conclusion could be drawn regarding the optimal timing of chest radiation. The aim of this study is to explore whether the timing of chest radiation may influence the survival of the patients with limited-stage small-cell lung cancer (LSSCLC) by performing a literature-based meta-analysis. ⋯ No statistical difference was observed in 2/3 years survival and toxicity, including pneumonitis, esophagitis and thrombocytopenia, between early radiation and late radiotherapy in LS-SCLC.